Page 130 - 南京医科大学学报自然科学版
P. 130
第41卷第11期
·1692 · 南 京 医 科 大 学 学 报 2021年11月
虽然研究者对基因编辑工具的在体转导方式 [8] KOCAK D D,JOSEPHS E A,BHANDARKAR V,et al.
进行了优化,但在转导效率、安全性、靶向性、致癌 Increasing the specificity of CRISPR systems with engi⁃
性等方面还存在诸多问题,亟待开发安全、高效的 neered RNA secondary structures[J]. Nat Biotechnol,
在体转导工具和小版本的 Cas 蛋白,以尽快打通基 2019,37(6):657-666
[9] SLAYMAKER I M,GAO L,ZETSCHE B,et al. Rationally
因编辑技术走向临床治疗的“最后一公里”。
engineered Cas9 nucleases with improved specificity[J].
4 总结与展望 Science,2016,351(6268):84-88
[10] KLEINSTIVER B P,PATTANAYAK V,PREW M S,et
从CRISPR⁃Cas9系统的发现到现在发展出了多 al. High⁃fidelity CRISPR⁃Cas9 nucleases with no detect⁃
种精准且多功能的基因编辑工具,在不到 8 年的时 able genome⁃wide off⁃target effects[J]. Nature,2016,529
间里,基因编辑技术的发展为新一代人类基因疗法 (7587):490-495
奠定了基础。尽管基因编辑工具仍存在脱靶和安 [11]CHEN J S,DAGDAS Y S,KLEINSTIVER B P,et al. En⁃
全风险,但其强大的功能和广泛的适用性,仍然是 hanced proofreading governs CRISPR⁃Cas9 targeting ac⁃
精准医疗的发展方向。随着基因编辑工具的不断 curacy[J]. Nature,2017,550(7676):407-410
[12] CASINI A,OLIVIERI M,PETRIS G,et al. A highly spe⁃
发展,以及在体转导方式的改进,将极大地促进基
cific SpCas9 variant is identified by in vivo screening in
因编辑技术走向临床应用。目前,尽管利用 CRIS⁃
yeast[J]. Nat Biotechnol,2018,36(3):265-271
PR系统进行基因治疗已经有很大突破,但将这一方 [13]LEE J K,JEONG E,LEE J,et al. Directed evolution of
法广泛运用到临床治疗中还有一段距离,仍面临着 CRISPR ⁃ Cas9 to increase its specificity[J]. Nat Com⁃
诸多挑战。相信不远的未来会开发出更加安全高 mun,2018,9(1):3048
效的编辑工具和在体转导体系,用于临床疾病的治 [14] SCHMID⁃BURGK J L,GAO L,LI D,et al. Highly paral⁃
疗。 lel profiling of Cas9 variant specificity[J]. Mol Cell,
2020,78(4):794-800.e8
[参考文献]
[15] JIANG F G,DOUDNA J A. CRISPR⁃cas9 structures and
[1] JINEK M,CHYLINSKI K,FONFARA I,et al. A program⁃ mechanisms[J]. Annu Rev Biophys,2017,46:505-529
mable dual⁃RNA⁃guided DNA endonuclease in adaptive [16] ENACHE O M,RENDO V,ABDUSAMAD M,et al. Cas9
bacterial immunity[J]. Science,2012,337(6096):816- activates the p53 pathway and selects for p53⁃inactivating
821 mutations[J]. Nat Genet,2020,52(7):662-668
[2] CONG L,RAN F A,COX D,et al. Multiplex genome engi⁃ [17] CHEW W L. Immunity to CRISPR Cas9 and Cas12a thera⁃
neering using CRISPR/Cas systems[J]. Science,2013, peutics[J]. Wiley Interdiscip Rev Syst Biol Med,2018,
339(6121):819-823 10(1). DOI:10.1002/wsbm.1408
[3] ANZALONE A V,RANDOLPH P B,DAVIS J R,et al. [18]KOMOR A C,KIM Y B,PACKER M S,et al. Programma⁃
Search⁃and⁃replace genome editing without double⁃strand ble editing of a target base in genomic DNA without dou⁃
breaks or donor DNA[J]. Nature,2019,576(7785):149- ble ⁃ stranded DNA cleavage[J]. Nature,2016,533
157 (7603):420-424
[4] ANZALONE A V,KOBLAN L W,LIU D R. Genome edit⁃ [19] GAUDELLI N M,KOMOR A C,REES H A,et al. Pro⁃
ing with CRISPR ⁃ Cas nucleases,base editors,trans⁃ grammable base editing of A·T to G·C in genomic DNA
posases and prime editors[J]. Nat Biotechnol,2020,38 without DNA cleavage[J]. Nature,2017,551(7681):
(7):824-844 464-471
[5] RAN F A,HSU P D,LIN C Y,et al. Double nicking by [20] KOMOR A C,ZHAO K T,PACKER M S,et al. Improved
RNA⁃guided CRISPR Cas9 for enhanced genome editing base excision repair inhibition and bacteriophage Mu
specificity[J]. Cell,2013,154(6):1380-1389 Gam protein yields C:G⁃to⁃T:a base editors with higher
[6] GUILINGER J P,THOMPSON D B,LIU D R. Fusion of efficiency and product purity[J]. Sci Adv,2017,3(8):
catalytically inactive Cas9 to FokI nuclease improves the eaao4774
specificity of genome modification[J]. Nat Biotechnol, [21] THURONYI B W,KOBLAN L W,LEVY J M,et al. Con⁃
2014,32(6):577-582 tinuous evolution of base editors with expanded target
[7] FU Y,SANDER J D,REYON D,et al. Improving CRISPR compatibility and improved activity[J]. Nat Biotechnol,
⁃Cas nuclease specificity using truncated guide RNAs[J]. 2019,37(9):1070-1079
Nat Biotechnol,2014,32(3):279-284 [22] KIM Y B,KOMOR A C,LEVY J M,et al. Increasing the